PEMBROLIZUMAB ADMINISTRATION ASSOCIATED with POSTERIOR UVEITIS

Retinal Cases and Brief Reports

Volumn 11, Issue 4, 2017, Pages 348-351

  Aaberg, Michael T ^a   Aaberg, Thomas M ^b  

^a DARTMOUTH COLLEGE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

eye; immunotherapy; melanoma; MK 3475; pembrolizumab; posterior uveitis; T cell; uveitis

Indexed keywords

DEXAMETHASONE; IPILIMUMAB; PEMBROLIZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLURRED VISION; CASE REPORT; CLINICAL ARTICLE; CONTINUOUS INFUSION; EYE ENUCLEATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; METASTATIC UVEA MELANOMA; MIDDLE AGED; PAPILLEDEMA; RADIOEMBOLIZATION; RELAPSE; RETINA VASCULITIS; SERODIAGNOSIS; SLIT LAMP MICROSCOPY; UVEITIS; VITREOUS FLOATERS; CHEMICALLY INDUCED; CHOROID TUMOR; MELANOMA; UVEA TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CHOROID NEOPLASMS; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; UVEAL NEOPLASMS; UVEITIS, POSTERIOR;

EID: 85032003638     PISSN: 19351089     EISSN: 19371578     Source Type: Journal    
DOI: 10.1097/ICB.0000000000000368     Document Type: Article

References (12)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
3. Michielin O, Hoeller C. Gaining momentum: new options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev 2015;41:660-670.
4. Jäger D. Potential target antigens for immunotherapy identified by serological expression cloning (serex). Methods Mol Biol 2007;360:319-326.
5. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-5283.
6. Pembrolizumab (Keytruda) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &Dohme Corp; 2014.
7. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilumumab-refractory melanoma (Keynote-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-918.
8. Merimsky O, Shoenfeld Y, Chaitchik S, et al. Antigens and antibodies in malignant melanoma. Tumor Biol 1994;15:188-202.
9. Klaska IP, Forrester JV. Mouse models of autoimmune uveitis. Curr Pharm Des 2015;21:2453-2467.
10. Manusow JS, Khoja L, Pesin N, et al. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer 2014;2:41.
11. Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol 2016;51:e4-e6.
12. Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 2016;26:e46-48.